

参考文献 (続き)

- Deschanvres C, Raffi F, Reynes J, et al. Virologic failure and resistance in dolutegravir-based maintenance dual regimens. Program and abstracts of the 2020 Conference on Retroviruses and Opportunistic Infections. March 8-11, 2020. Boston, Massachusetts (Virtual). Abstract 490.
- Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. *Lancet*. 1999;353:2195-2199.
- Emu B, Lalezari J, Kumar P, et al. Ibalizumab: 96-week data and efficacy in patients resistant to common antiretrovirals. Program and abstracts of the 2019 Conference on Retroviruses and Opportunistic Infections. March 4-7, 2019. Seattle, WA. Abstract 485.
- European AIDS Clinical Society. EACS Guidelines, version 10.1. October 2020. Available at: <https://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html>. Accessed May 12, 2021.
- Gagliardini R, Ciccullo A, Borghetti A, et al. Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study. *Open Forum Infect Dis*. 2018;5(6):ofy113.
- GlaxoSmithKline. Rukobia US prescribing information. Available at: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/RUKOBIA/pdf/RUKOBIA-PI-PIL.PDF. August 2020. Accessed May 12, 2021.
- Gilead Sciences. Sunlenca US prescribing information. Available at: https://www.sunlencahcp.com/?gclid=CjwKCAjwolqhBhAGEiwArXT7K3T_5diMoR_TyxIthNjEle8OTGYo65VKz0vOhQp2JcFqUjUTwGIVQBoCMXQQAvD_BwE&gclid=aw.ds
- Goetz M, Leduc R, Kostman J, et al. HIV replicative capacity is an independent predictor of disease progression in persons with untreated chronic HIV infection. *J Acquir Immune Defic Syndr*. 2010;53:472-479.
- Hardy I, Brenner B, Quashie P, Thomas R, Petropoulos C, Huang W, Moisi D, Wainberg MA, and Roger M. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. *J Antimicrob Chemother*. 2015;70(2):405-411.
- Hatano H, Lampiris H, Fransen S, et al. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2010;54:389-393.